Bachem
  • Products & Services
    • CMC Development
      • Peptide NCEs
      • Oligonucleotide NCEs
    • Commercial API
      • Commercial NCEs
      • Commercial Generics
    • Research & Specialties
      • Catalog Peptides
      • Custom Peptide Synthesis
      • Amino Acid Derivatives
      • Diagnostics
      • Cosmetic Peptides
    • Services & Capabilities
      • Project Management
      • Quality & Regulatory
      • Analytical capabilities
      • GMP Production
      • Research Grade Production
      • Supply & vertical integration
  • About Bachem
    • Company overview
      • Our Purpose
      • Our vision & strategy
      • Our Leadership
      • Our History
      • Our Locations
    • Innovation
      • Innovation matters
      • Innovation collaborations
    • Sustainability
      • People & culture
      • Safeguarding the environment
      • Acting ethically
    • Investors & Media
      • Reports & Presentations
      • Financial events
      • Media Library
      • Press archive
  • News & Events
    • News
    • Events
  • Careers
  • Contact
Select Page

Results of the capital increase

May 08, 2019
Only available in the German version.

Download

test theme builder local clear 256mb

← Peptide Trends April 2019 Peptide Trends May 2019 →

Innovation transforming oligonucleotide manufacturing

Bachem Earns Gold Medal Sustainability Rating from EcoVadis

Bachem Annual General Meeting 2022

Bachem enters strategic collaboration with Lilly to manufacture oligonucleotide-based drug substances

A passion for shaping the future of Bachem: Interview with Diana Rinderle

Bachem’s new facilities for large-scale oligonucleotide manufacturing

Bachem achieves sales of half a billion Swiss francs

Cell-penetrating peptides: a delivery system for oligonucleotides

Bachem in Oligonucleotides: Interview with Seamus White

The thiol-maleimide reaction downside

Changes to the Bachem CEC and strengthening of the US organization

Assessing and Influencing ACE2-Mediated COVID-19 Infection

Bachem lays foundations for company’s largest production building

Bachem raises CHF 583.5 million through capital increase

Bachem launches accelerated bookbuilding for approx. 750k new shares

Extraordinary General Meeting

How are Peptides Made?

Bachem’s Commitment to Sustainability

Bachem intends a capital increase – construction of additional manufacturing site

Bachem’s liraglutide: a high-purity generic for diabetes and weight loss

Knowledge Center
General Conditions
Legal Statement
Privacy Policy
Imprint
Contact
  •  

  •  

  •  

  •  

  •